Gena Wang
Stock Analyst at Barclays
(2.38)
# 2,509
Out of 4,944 analysts
215
Total ratings
42.45%
Success rate
-1.13%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gena Wang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RGNX REGENXBIO | Maintains: Overweight | $50 → $37 | $8.93 | +314.33% | 7 | Aug 8, 2025 | |
| RNA Avidity Biosciences | Maintains: Overweight | $59 → $62 | $46.15 | +34.34% | 4 | Aug 8, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Equal-Weight | $42 → $56 | $57.33 | -2.32% | 17 | Aug 6, 2025 | |
| BEAM Beam Therapeutics | Maintains: Equal-Weight | $25 → $21 | $17.52 | +19.86% | 10 | Aug 6, 2025 | |
| MRNA Moderna | Maintains: Equal-Weight | $40 → $31 | $26.89 | +15.28% | 10 | Aug 4, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Overweight | $329 → $460 | $432.52 | +6.35% | 8 | Aug 1, 2025 | |
| SRPT Sarepta Therapeutics | Upgrades: Equal-Weight | $10 → $22 | $20.40 | +7.84% | 15 | Jul 30, 2025 | |
| PTCT PTC Therapeutics | Maintains: Equal-Weight | $42 → $46 | $48.17 | -4.50% | 16 | Jul 29, 2025 | |
| IONS Ionis Pharmaceuticals | Upgrades: Overweight | $51 → $57 | $43.10 | +32.25% | 10 | Jul 1, 2025 | |
| SLDB Solid Biosciences | Maintains: Overweight | $15 → $10 | $6.68 | +49.70% | 7 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $5 | $0.54 | +826.61% | 4 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $2.79 | +43.37% | 4 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $38 | $6.67 | +469.72% | 2 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 → $53 | $36.88 | +43.71% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $11 | $8.53 | +28.96% | 10 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $31 | $4.57 | +578.34% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 → $26 | $11.00 | +136.36% | 7 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $435 → $467 | $395.92 | +17.95% | 17 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $3.08 | -2.60% | 9 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $3 → $4 | $8.62 | -53.60% | 8 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $86 | $58.30 | +47.51% | 15 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $83 → $81 | $28.97 | +179.60% | 6 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $94 | $36.93 | +154.54% | 6 | Jan 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $9 | $13.94 | -35.44% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $16 → $25 | $19.21 | +30.14% | 5 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $18 | $8.34 | +115.83% | 2 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $21 → $9 | $5.30 | +69.81% | 6 | Aug 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $275 | $6.56 | +4,092.07% | 1 | Jan 6, 2017 |
REGENXBIO
Aug 8, 2025
Maintains: Overweight
Price Target: $50 → $37
Current: $8.93
Upside: +314.33%
Avidity Biosciences
Aug 8, 2025
Maintains: Overweight
Price Target: $59 → $62
Current: $46.15
Upside: +34.34%
CRISPR Therapeutics AG
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $42 → $56
Current: $57.33
Upside: -2.32%
Beam Therapeutics
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $25 → $21
Current: $17.52
Upside: +19.86%
Moderna
Aug 4, 2025
Maintains: Equal-Weight
Price Target: $40 → $31
Current: $26.89
Upside: +15.28%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Overweight
Price Target: $329 → $460
Current: $432.52
Upside: +6.35%
Sarepta Therapeutics
Jul 30, 2025
Upgrades: Equal-Weight
Price Target: $10 → $22
Current: $20.40
Upside: +7.84%
PTC Therapeutics
Jul 29, 2025
Maintains: Equal-Weight
Price Target: $42 → $46
Current: $48.17
Upside: -4.50%
Ionis Pharmaceuticals
Jul 1, 2025
Upgrades: Overweight
Price Target: $51 → $57
Current: $43.10
Upside: +32.25%
Solid Biosciences
May 16, 2025
Maintains: Overweight
Price Target: $15 → $10
Current: $6.68
Upside: +49.70%
May 14, 2025
Maintains: Overweight
Price Target: $9 → $5
Current: $0.54
Upside: +826.61%
May 13, 2025
Maintains: Overweight
Price Target: $5 → $4
Current: $2.79
Upside: +43.37%
May 9, 2025
Maintains: Overweight
Price Target: $45 → $38
Current: $6.67
Upside: +469.72%
May 8, 2025
Maintains: Overweight
Price Target: $55 → $53
Current: $36.88
Upside: +43.71%
May 7, 2025
Maintains: Equal-Weight
Price Target: $8 → $11
Current: $8.53
Upside: +28.96%
Feb 28, 2025
Maintains: Overweight
Price Target: $26 → $31
Current: $4.57
Upside: +578.34%
Feb 28, 2025
Maintains: Overweight
Price Target: $55 → $26
Current: $11.00
Upside: +136.36%
Feb 11, 2025
Maintains: Equal-Weight
Price Target: $435 → $467
Current: $395.92
Upside: +17.95%
Dec 13, 2024
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $3.08
Upside: -2.60%
Nov 15, 2024
Maintains: Underweight
Price Target: $3 → $4
Current: $8.62
Upside: -53.60%
Oct 4, 2024
Maintains: Overweight
Price Target: $110 → $86
Current: $58.30
Upside: +47.51%
Aug 5, 2024
Maintains: Overweight
Price Target: $83 → $81
Current: $28.97
Upside: +179.60%
Jan 24, 2024
Maintains: Overweight
Price Target: $93 → $94
Current: $36.93
Upside: +154.54%
Dec 22, 2022
Maintains: Equal-Weight
Price Target: $7 → $9
Current: $13.94
Upside: -35.44%
Nov 2, 2022
Upgrades: Equal-Weight
Price Target: $16 → $25
Current: $19.21
Upside: +30.14%
May 13, 2022
Maintains: Overweight
Price Target: $32 → $18
Current: $8.34
Upside: +115.83%
Aug 9, 2019
Maintains: Underweight
Price Target: $21 → $9
Current: $5.30
Upside: +69.81%
Jan 6, 2017
Initiates: Buy
Price Target: $275
Current: $6.56
Upside: +4,092.07%